When was Deciphera founded?

Deciphera was founded in 2003 and raised its 1st funding round 11 years after it was founded.

Where is Deciphera located?

Deciphera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts.

How many employees does Deciphera have?

As of Sep 30, 2026, the latest employee count at Deciphera is 563.

Is Deciphera a funded company?

Deciphera is a funded company, having raised a total of $173M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 2014.

How much is Deciphera worth?

The last known valuation of Deciphera was $***** as of Apr 29, 2024.

When was the latest funding round of Deciphera?

Deciphera's latest funding was a $***** Series C round on Jun 05, 2017, with participation from 4 investors.

What is the annual revenue of Deciphera?

Annual revenue of Deciphera is between $100M and $500M as on Dec 31, 2023

Where does Deciphera rank among its competitors?

Deciphera ranks 65th amongst 3308 active competitors, of which 1117 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Deciphera?

Deciphera's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Deciphera - 2026 Company Profile, Funding & Competitors

Company Details

Developer of type 2 kinase inhibitors for treating cancer. The company leverages proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of medicines for the treatment of cancer.

Website: www.deciphera.com/
Registered Address: Waltham, Massachusetts

Key Metrics

Founded Year

2003

Location

Waltham, United States

Stage

Acquired

Total Funding

$173M in 3 rounds

Latest Funding Round

Series C, Jun 05, 2017, $*****

Last Known Valuation

$***** as on Apr 29, 2024

Investors

New Leaf Venture Partners & 5 more

Ranked

65^th among 3308 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2023

Employee Count

563 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2985 more

Exit Details

Acquired by ONO PHARMACEUTICAL (Apr 29, 2024)

View Deciphera's full profile

Deciphera is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Deciphera Pharmaceuticals, Inc. CIN: 1654151 , United States, Active	Jul 31, 2017	$100M - $500M (As on Dec 31, 2023)	-	-
DECIPHERA PHARMACEUTICALS, LLC CIN: 200299725 , United States, Active	Dec 31, 2002	-	332 (As on Dec 31, 2024)	-

Deciphera got acquired by ONO PHARMACEUTICAL on Apr 29, 2024 at an acquisition amount of $*****.

Click here to take a look at Deciphera's acquisition in detail

Deciphera has raised a total funding of $173M over 3 rounds. Its first funding round was on Apr 2014. Its latest funding round was a Series C round on Jun 05, 2017 for $*****. 4 investors participated in its latest round. Deciphera has 6 institutional investors.

Here is the list of recent funding rounds of Deciphera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 05, 2017	4627079	Series C	1554408	9178920	3300817	2409236
Jul 13, 2016	2451709	Series B	7789224	4785029	1661579	SV Health Investors
Apr 2014	2248489	Series A	9472358	1207314	8907270	Lilly

Access funding benchmarks and valuations. Sign up today!

View details of Deciphera's funding rounds and investors

Deciphera's employee count trend

Deciphera has 563 employees as of Sep 26. Here is Deciphera's employee count trend over the years:

Uncover Deciphera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Deciphera include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Deciphera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
65th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100